Kala Pharmaceuticals (NASDAQ: KALA) reported Q4 EPS of ($0.63), $0.03 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $2.95 million.

For earnings history and earnings-related data on Kala Pharmaceuticals (KALA) click here.